Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications—A Narrative Review
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27146116 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Sandro La Vignera und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. Hauptthemen laut MEDLINE: Incretins, Doping in Sports, Athletic Performance, Performance-Enhancing Substances. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Incretin-based therapies, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, have revolutionized the management of type 2 diabetes and obesity. Recent evidence suggests these agents may influence athletic performance through effects on body composition, energy metabolism, and cardiovascular function. This narrative review critically evaluates whether incretin therapies could constitute doping under World Anti-Doping Agency (WADA) criteria. We narratively reviewed the literature on incretin pharmacology, metabolic effects relevant to athletic performance, and anti-doping regulations, searching PubMed, Scopus, and Web of Science using terms including “GLP-1 receptor agonists”, “DPP-4 inhibitors”, “doping”, “athletic performance”, “WADA”, and “sports pharmacology”, without date restrictions. GLP-1 RAs (semaglutide, liraglutide, tirzepatide, exenatide) induce substantial weight loss (predominantly fat mass) but also reduce lean mass by 20–30% of total weight loss. Preclinical studies demonstrate enhanced exercise endurance, mitochondrial biogenesis, and glucose uptake via GLP-1R/AMPK signaling. However, clinical trials show no consistent improvement in physical performance in humans. Currently, incretin therapies are not listed on the WADA Prohibited List. While incretin therapies offer theoretical performance-enhancing potential through weight management and metabolic optimization, current evidence does not support classification as doping agents. Continued surveillance is warranted as misuse patterns emerge.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy.
ORCID-Profile: Sandro La Vignera, Rosita A Condorelli
Zitieren
APA
La Vignera, S., & Condorelli, R. A. (2026). Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications—A Narrative Review. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27146116
Vancouver
La Vignera S, Condorelli RA. Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications—A Narrative Review. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27146116
BibTeX
@article{LaVignera2026,
author = {La Vignera, Sandro and Condorelli, Rosita A},
title = {Incretin-Based Therapies in Sports: Pharmacological Mechanisms, Performance-Enhancing Potential, and Anti-Doping Implications—A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27146116}
}
EUVIMED